Many drug-resistant tumors have dysfunctional metabolism of ceramide, a metabolite that promotes cell death.
Investigators who previously demonstrated that augmenting ceramide can counter tumors’ drug resistance mechanisms have now shown that adding ceramide nanoliposomes can improve the efficacy of a standard chemotherapy regimen of venetoclax plus cytarabine in models of acute myeloid leukemia.
In their study published in The FASEB Journal, the researchers also uncovered several mechanisms behind these effects.
Source: Read Full Article